Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.
暂无分享,去创建一个
[1] A. Szegedi,et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. , 1996, The Journal of clinical psychiatry.
[2] D. Nierenberg,et al. The central nervous system serotonin syndrome , 1993, Clinical pharmacology and therapeutics.
[3] R. Sandyk. L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. , 1986, Journal of clinical psychopharmacology.
[4] A. Sleight,et al. Relationship between extracellular 5‐hydroxytryptamine and behaviour following monoamine oxidase inhibition and l‐tryptophan , 1988, British journal of pharmacology.
[5] P. Nijhawan,et al. Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. , 1996, Critical care medicine.
[6] HarveyA. Sternbach. DANGER OF MAOI THERAPY AFTER FLUOXETINE WITHDRAWAL , 1988, The Lancet.
[7] P. Blier,et al. The safety of concomitant use of sumatriptan and antidepressant treatments. , 1995, Journal of clinical psychopharmacology.
[8] M. Robbins,et al. Sertraline intoxication in a child. , 1994, Annals of emergency medicine.
[9] A. Nierenberg,et al. Trazodone for antidepressant-associated insomnia. , 1994, The American journal of psychiatry.
[10] O. Spigset,et al. Serotonin syndrome caused by a moclobemide-clomipramine interaction. , 1993, BMJ.
[11] D. Coulter,et al. Hypertension with moclobemide , 1995, The Lancet.
[12] I. Boyd. Hypertension with moclobemide , 1995, The Lancet.
[13] P. Cowen,et al. Fluoxetine and Suicidal Behaviour , 1992, British Journal of Psychiatry.
[14] I. M. Vigran. DANGEROUS POTENTIATION OF MEPERIDINE HYDROCHLORIDE BY PARGYLINE HYDROCHLORIDE. , 1964, JAMA.
[15] R. Mitchell. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. , 1955, Annals of internal medicine.
[16] G. Rutherford,et al. Use of hospitals by patients with AIDS in San Francisco. , 1988, The New England journal of medicine.
[17] A. Hadley,et al. Mania resulting from lithium-fluoxetine combination. , 1989, The American journal of psychiatry.
[18] S. Nimmo,et al. Drug‐induced hyperthermia , 1993, Anaesthesia.
[19] M. Corkeron. Serotonin syndrome — a potentially fatal complication of antidepressant therapy , 1995, The Medical journal of Australia.
[20] J. Dingemanse,et al. Moclobemide and fluvoxamine co‐administration: A prospective study in healty volunteers to investigate the potential development of the ‘serotonin syndrome’ , 1995 .
[21] A. Gelenberg. Polypharmacy in Psychiatry , 1995 .
[22] A. Salama,et al. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. , 1989, The American journal of psychiatry.
[23] S. Preskorn,et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.
[24] D. Murphy,et al. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. , 1991, Journal of clinical psychopharmacology.
[25] R. Roth,et al. 3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. , 1990, European journal of pharmacology.
[26] D. Meyer,et al. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. , 1981, Journal of clinical psychopharmacology.
[27] R. Joffe,et al. Combined SSRI-moclobemide treatment of psychiatric illness. , 1994, The Journal of clinical psychiatry.
[28] M. Bauer,et al. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. , 1996, Journal of Clinical Psychopharmacology.
[29] T. Lüscher,et al. Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.
[30] A. Freemont,et al. Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.
[31] S. Toyama,et al. Is it Safe to Combine a Selective Serotonin Reuptake Inhibitor with Selegiline? , 1994, The Annals of pharmacotherapy.
[32] D. Ames,et al. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link? , 1993, JAMA.
[33] A. Shah,et al. Case report: Acute confusional state secondary to a combination of fluoxetine and lithium , 1992 .
[34] S. Platman,et al. Potentiation of a monoamine oxidase inhibitor by tryptophan. , 1969, Journal of psychiatric research.
[35] R. Zerbe,et al. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. , 1993, Journal of clinical psychopharmacology.
[36] M. Leung,et al. Lack of an Interaction Between Sumatriptan and Selective Serotonin Reuptake Inhibitors , 1995, Headache.
[37] O. Suchowersky,et al. Interaction of Fluoxetine and Selegiline , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[38] W. Harrison,et al. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? , 1995, The Journal of clinical psychiatry.
[39] R. Lappin,et al. Treatment of the serotonin syndrome with cyproheptadine. , 1994, The New England journal of medicine.
[40] N. C. Reid,et al. Pethidine and Phenelzine , 1962 .
[41] J. Osterloh,et al. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') , 1987, JAMA.
[42] G. Keepers,et al. Interaction of fluoxetine and pentazocine. , 1990, The American journal of psychiatry.
[43] K. Otani,et al. Inhibition of Trazodone Metabolism by Thioridazine in Humans , 1995, Therapeutic drug monitoring.
[44] Joffe Rt,et al. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. , 1993 .
[45] S. Dursun,et al. Toxic serotonin syndrome after fluoxetine plus carbamazepine , 1993, The Lancet.
[46] F. Ruiz. Fluoxetine and the serotonin syndrome. , 1994, Annals of emergency medicine.
[47] Coplan Jd,et al. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. , 1993 .
[48] G. Kaskey. Possible interaction between an MAOI and "ecstasy". , 1992, The American journal of psychiatry.
[49] J. Feighner,et al. Adverse consequences of fluoxetine-MAOI combination therapy. , 1990, The Journal of clinical psychiatry.
[50] A. Delini-Stula,et al. Risk of 5-HT syndrome after co-administration of moclobemide (RIMA) and selective 5-HT re-uptake inhibitors (SSRI) — analysis of cases , 1993, European Neuropsychopharmacology.
[51] W. Steiner,et al. Toxic reaction following the combined administration of fluoxetine and l-tryptophan: Five case reports , 1986, Biological Psychiatry.
[52] D. Steffens,et al. Serotonin syndrome produced by a combination of fluoxetine and lithium. , 1993, The American journal of psychiatry.
[53] S. Sindrup,et al. Citalopram: Interaction Studies with Levomepromazine, Imipramine, and Lithium , 1993, Therapeutic drug monitoring.
[54] H. Sternbach. The serotonin syndrome. , 1991, The American journal of psychiatry.
[55] Noveske Fg,et al. Possible toxicity of combined fluoxetine and lithium. , 1989 .
[56] M. Baetz,et al. Serotonin Syndrome from Fluvoxamine and Buspirone , 1995, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[57] L. Bowen. Fatal Hyperpyrexia with Antidepressant Drugs , 1964, British medical journal.
[58] K. Nisijima,et al. Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy , 1996, Biological Psychiatry.
[59] O. Spigset,et al. Serotonin syndrome induced by fluvoxamine-lithium interaction. , 1993, Pharmacopsychiatry.
[60] D. Jermain,et al. Potential Fluoxetine—Selegiline Interaction , 1992, The Annals of pharmacotherapy.
[61] J. Dingemanse. An update of recent moclobemide interaction data , 1993, International clinical psychopharmacology.
[62] D. Baldwin,et al. Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions , 1994, International clinical psychopharmacology.
[63] D. Goldbloom,et al. Fluoxetine and neuroleptic malignant syndrome , 1990, Biological Psychiatry.
[64] A. Sjoerdsma,et al. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor , 1960, Neurology.
[65] U. Davies,et al. Landmarks for the insertion of oesophageal endoprosthesis. , 1992 .
[66] S. Zail,et al. Effect of ethanol on liver 8-aminolaevulinate synthetase in rats. , 1968 .
[67] J. Shee. Dangerous Potentiation of Pethidine by Iproniazid, and its Treatment , 1960, British medical journal.
[68] L. Kofoed,et al. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. , 1994, American journal of hospital pharmacy.
[69] B. Rumack,et al. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. , 1987, Journal of toxicology. Clinical toxicology.
[70] Philip R. Cohen,et al. Lithium in Tricyclic-Resistant Depression Correlation of Increased Brain 5-HT Function with Clinical Outcome , 1991, British Journal of Psychiatry.
[71] A. Ontiveros,et al. Refractory depression: the addition of lithium to fluoxetine or desipramine , 1991, Acta psychiatrica Scandinavica.
[72] B. Seitanidis,et al. T LYMPHOCYTES IN INFECTIOUS MONONUCLEOSIS , 1974 .
[73] G. Simpson,et al. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. , 1981, Journal of clinical psychopharmacology.
[74] G. Addonizio,et al. Reinduction of Neuroleptic Malignant Syndrome by Lithium , 1987, Journal of clinical psychopharmacology.
[75] K. Wozniak,et al. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors , 1983, Psychological Medicine.
[76] T. Dinan,et al. Lithium augmentation in sertraline‐resistant depression: a preliminary dose‐response study , 1993, Acta psychiatrica Scandinavica.
[77] D. Taylor. ALARMING REACTION TO PETHIDINE IN PATIENTS ON PHENELZINE , 1962 .
[78] A. T. Harvey,et al. Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. , 1995, The American journal of emergency medicine.
[79] M. Lejoyeux,et al. Serotonin Syndrome , 1994 .
[80] S. Dawling,et al. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.
[81] M. Graber,et al. Sertraline-Phenelzine Drug Interaction: A Serotonin Syndrome Reaction , 1994, The Annals of pharmacotherapy.
[82] O. Rascol,et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline , 1993, The Lancet.
[83] L. Baxter,et al. The serotonin syndrome: case responsive to propranolol. , 1986, Journal of clinical psychopharmacology.
[84] W. Bushnell,et al. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. , 1995, The Journal of clinical psychiatry.
[85] M. Marino,et al. Interaction of nefazodone (N) and fluoxetine (F) , 1996 .
[86] M. Norden. Buspirone treatment of sexual dysfunction associated with selective serotonin re‐uptake inhibitors , 1994 .
[87] H. Palmer. Potentiation of Pethidine , 1960 .
[88] D. Marazziti,et al. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage. , 1993, Pharmacopsychiatry.
[89] Achamallah Ns. VISUAL HALLUCINATIONS AFTER COMBINING FLUOXETINE AND DEXTROMETHORPHAN , 1992 .
[90] E. Azmitia,et al. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.
[91] R. Reeves,et al. Serotonin syndrome produced by paroxetine and low-dose trazodone. , 1995, Psychosomatics.
[92] R. Goldberg,et al. Serotonin syndrome from trazodone and buspirone. , 1992, Psychosomatics.
[93] K. Bergmann,et al. Combination Treatment with Noradrenalin and Serotonin Reuptake Inhibitors in Resistant Depression , 1992, British Journal of Psychiatry.
[94] T. R. Brodribb,et al. Efficacy and adverse effects of moclobemide , 1994, The Lancet.
[95] H. Wildgust,et al. The combination of fluoxetine and lithium in clinical practice , 1993, International clinical psychopharmacology.
[96] W. Haefely,et al. Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. , 1983, Modern problems of pharmacopsychiatry.
[97] C. Bowden,et al. Sertraline and isocarboxazid cause a serotonin syndrome. , 1994, Journal of clinical psychopharmacology.
[98] S. Dursun,et al. Toxic serotonin syndrome or extrapyramidal side-effects? , 1995, British Journal of Psychiatry.
[99] G. Screaton,et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.
[100] M. Floris,et al. A CONTROLLED PILOT STUDY OF THE COMBINATION OF FLUVOXAMINE AND LITHIUM , 1991 .
[101] P. Waller,et al. Safety of fluoxetine: Comparison with fluvoxamine , 1992 .
[102] R. Tackley,et al. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction , 1987, Anaesthesia.
[103] T. M. Brown,et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. , 1994, The American journal of emergency medicine.
[104] J. Lieberman,et al. Neuromuscular effects of monoamine oxidase inhibitors. , 1985, Journal of clinical psychopharmacology.
[105] R. Bost,et al. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.
[106] A. Ceccherini-Nelli,et al. Fluoxetine: the relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa , 1993, International clinical psychopharmacology.
[107] C. Callaway,et al. Hyperthermia in psychostimulant overdose. , 1994, Annals of emergency medicine.
[108] J. Dingemanse. Pharmacological interactions with reversible MAOIs and clinical relevance , 1993, European Neuropsychopharmacology.
[109] D. Faulds,et al. Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness. , 1992, Drugs.
[110] C. Lowenstein,et al. Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.
[111] P. Neuvonen,et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses , 1993, The Lancet.
[112] M. Evans,et al. Fluvoxamine and lithium: an unusual interaction , 1990, British Journal of Psychiatry.
[113] H. Miyaoka,et al. Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? , 1995, International clinical psychopharmacology.
[114] T. Randall. Ecstasy-fueled 'rave' parties become dances of death for English youths. , 1992, JAMA.
[115] N. Rivers,et al. Possible lethal reaction between nardil and dextromethorphan. , 1970, Canadian Medical Association journal.
[116] G. Tucker,et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. , 1992, British journal of clinical pharmacology.
[117] Schen Rj. Letter: Chlorpropamide hypoglycaemia. , 1973 .